Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. | Available online http content 10 6 R160 Research Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis Christopher Gonano1 2 Christian Sitzwohl1 Eva Meitner1 Christian Weinstabl1 and Stephan C Kettner1 1 Department of Anesthesiology and General Intensive Care Medical University of Vienna Waehringer Gurtel 18-20 A-1090 Vienna Austria 2Austrian Anesthesiology and Critical Care Foundation Vienna Austria Corresponding author Stephan C Kettner Received 24 Apr 2006 Revisions requested 22 Jun 2006 Revisions received 21 Oct 2006 Accepted 15 Nov 2006 Published 15 Nov 2006 Critical Care 2006 10 R160 doi cc5098 This article is online at http content 10 6 R160 2006 Gonano et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction Sepsis activates the coagulation system and frequently causes hypercoagulability which is not detected by routine coagulation tests. A reliable method to evaluate hypercoagulability is thromboelastography TEG but this has not so far been used to investigate sepsis-induced hypercoagulability. Antithrombin AT in plasma of septic patients is decreased and administration of AT may therefore reduce the acquired hypercoagulability. Not clear however is to what extent supraphysiologic plasma levels of AT decrease the acute hypercoagulability in septic patients. The present study investigates the coagulation profile of septic patients before and during four day high-dose AT therapy. Methods Patients with severe sepsis were randomly assigned to receive either 6 000 IU AT as a bolus infusion followed by a maintenance dose of 250 IU hour over four days n 17 or placebo n 16
